Patents Examined by Nicole Kinsey
-
Patent number: 11952401Abstract: The present disclosure belongs to the technical field of biological products for veterinary medicine, and specifically relates to a recombinant foot-and-mouth disease virus (FMDV) with a reduced immunosuppressive activity, a preparation method and use thereof, and a recombinant vaccine strain. According to the present disclosure, it is firstly discovered that FMDV 3B protein has an immunosuppressive function, and key sites for exerting the immunosuppressive function are found. A recombinant FMDV vaccine strain with a lost immunosuppressive function in FMDV 3B protein is constructed by introducing amino acid mutations into three repeated copies of FMDV 3B protein.Type: GrantFiled: July 14, 2021Date of Patent: April 9, 2024Assignee: Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural SciencesInventors: Haixue Zheng, Fan Yang, Zixiang Zhu, Xiangle Zhang, Weijun Cao, Congcong Wang, Kangli Li, Huisheng Liu, Hong Tian, Keshan Zhang, Xiangtao Liu
-
Patent number: 11952594Abstract: The present invention relates to the delivery of a payload by bacterial delivery vehicle, i.e. the encapsulation and the delivery of a single plasmid by different bacterial virus particles. More specifically, the present invention concerns a pharmaceutical composition comprising a payload packaged in at least two different bacterial delivery vehicles and a method of production thereof.Type: GrantFiled: August 19, 2021Date of Patent: April 9, 2024Assignee: ELIGO BIOSCIENCEInventors: Antoine Decrulle, Xavier Duportet, Igor Stzepourginski
-
Patent number: 11944682Abstract: Aggregation-induced emission-bacteriophage bioconjugate including a bacteriophage covalently bonded to at least one aggregation-induced emission luminogen via an optional linker, pharmaceutical compositions including the same, and methods of preparation and use thereof.Type: GrantFiled: January 22, 2021Date of Patent: April 2, 2024Assignee: The Hong Kong University of Science and TechnologyyInventors: Benzhong Tang, Xuewen He
-
Patent number: 11926877Abstract: A saliva-based testing method that bypasses the need for RNA isolation/purification is described herein. In experiments with inactivated SARS-CoV-2 virus spiked into saliva, this method has a limit of detection of 500-1000 viral particles per mL, rivalling the standard NP swab method. Initial studies showed excellent performance with 100 clinical samples. This saliva-based process is operationally simple, utilizes readily available materials, and can be easily implemented by existing testing sites thus allowing for high-throughput, rapid, and repeat testing of large populations.Type: GrantFiled: June 17, 2021Date of Patent: March 12, 2024Assignee: The Board of Trustees of the University of IllinoisInventors: Diana Rose Ranoa, Robin L. Holland, Fadi G. Alnaji, Kelsie J. Green, Leyi Wang, Christopher B. Brooke, Martin D. Burke, Timothy M. Fan, Paul J. Hergenrother
-
Patent number: 11918639Abstract: The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.Type: GrantFiled: October 11, 2021Date of Patent: March 5, 2024Assignees: Bavarian Nordic A/S, Janssen Vaccines & Prevention B.V., The United States of America, as represented by The Secretary, Department of Health and Human ServiceInventors: Ariane Volkmann, Robin Steigerwald, Ulrike Dirmeier, Maria Grazia Pau, Benoit Christophe Stephan Callendret, Lucy A. Ward
-
Patent number: 11918642Abstract: Disclosed are compositions for generating an immune response against human immunodeficiency virus (HIV) and their methods of uses.Type: GrantFiled: September 29, 2021Date of Patent: March 5, 2024Assignee: Arizona Board of Regents on Behalf of Arizona State UniversityInventors: Tsafrir S. Leket-Mor, Bertram Jacobs, Lydia Meador, Karen Kibler
-
Patent number: 11920149Abstract: The present invention relates to nucleic acid regulatory elements that are able to enhance diaphragm-specific expression of genes, in particular expression in diaphragm as such, or in combination with expression in cardiac muscle and/or skeletal muscle, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy, more particularly diaphragm-directed gene therapy, and for vaccination purposes.Type: GrantFiled: March 27, 2018Date of Patent: March 5, 2024Assignee: VRIJE UNIVERSITEIT BRUSSELInventors: Lay Khim Chuah, Thierry Vandendriessche, Warut Tulalamba
-
Patent number: 11918638Abstract: Reported herein are novel recombinant respiratory syncytial viruses (RSV) having an attenuated phenotype in which the native positions of the NS1 and/or NS2 genes in the RSV genome are shifted to a higher position, that is at positions that are more distal to the promoter. The changes in the gene positions may be present in combination with mutations at other loci to achieve desired levels of attenuation and immunogenicity. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.Type: GrantFiled: February 23, 2021Date of Patent: March 5, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter L. Collins, Thomas Charles McCarty
-
Patent number: 11911458Abstract: The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.Type: GrantFiled: July 7, 2017Date of Patent: February 27, 2024Assignee: American Gene Technologies International Inc.Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Gary Mansfield
-
Patent number: 11898171Abstract: Provided is a method and composition using ROS to increase the production of bacteriophage. According to the subject matter, a production amount of bacteriophage is increased several times in the presence of the sublethal concentration of ROS for host bacteria. Therefore, the method and composition of the subject matter can be useful for producing bacteriophage, which is used as an alternative to antibiotics that cause a serious resistance problem.Type: GrantFiled: August 22, 2018Date of Patent: February 13, 2024Assignee: LYSENTECHInventors: Heejoon Myung, Yunyeol Jo
-
Patent number: 11896633Abstract: Provided are engineered phages populations, which are homogeneous in length, as well as methods of making and methods of using such phages. Also provided are engineered chlorotoxin-phages as well as their methods of making and using. The disclosed homogeneous phage populations and chlorotoxin-phages may be used, for example, for treating and/or imaging tumors, such as central nervous system tumors.Type: GrantFiled: March 22, 2021Date of Patent: February 13, 2024Assignee: Massachusetts Institute of TechnologyInventors: Angela M. Belcher, Uyanga Tsedev, Fred Lam
-
Patent number: 11883482Abstract: The disclosure provides a recombinant nucleic acid of Seneca valley virus, a recombinant vaccine strain and preparation method and use thereof, and relates to the technical field of genetic engineering. The disclosure provides the recombinant nucleic acid of Seneca valley virus, recombinant Seneca valley virus comprising the recombinant nucleic acid, recombinant Seneca valley virus encoded by the recombinant nucleic acid, recombinant Seneca valley virus vaccine strain comprising the recombinant Seneca valley virus and preparation method and use thereof. According to the disclosure, a vaccine strain characterized by high antigen production capacity, remarkably reduced pathogenicity (even having no pathogenicity to pigs), strong antibody induction activity, high immune protection rate is prepared. The vaccine strain remarkably improves the biological safety and can be used for preventing and controlling Seneca valley virus in China and the neighboring countries.Type: GrantFiled: May 24, 2021Date of Patent: January 30, 2024Inventors: Haixue Zheng, Fan Yang, Zixiang Zhu, Weijun Cao, Hong Tian, Keshan Zhang, Ting Wei, Min Zheng, Wei Zhang, Wen Dang, Xusheng Ma, Dan Li, Yi Ru, Jijun He, Jianhong Guo, Xiangtao Liu
-
Patent number: 11872278Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.Type: GrantFiled: June 10, 2020Date of Patent: January 16, 2024Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Sunny Himansu
-
Patent number: 11851672Abstract: The present invention provides a kit of vectors for transducing an immune cell with multiple transgenes comprising: (i) a first vector which comprises a first transgene and a nucleotide sequence encoding a transcription factor and; and (ii) a second vector which comprises a second transgene wherein expression of the second transgene within a host cell is dependent upon expression of the transcription factor.Type: GrantFiled: October 24, 2018Date of Patent: December 26, 2023Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, James Sillibourne, Shaun Cordoba
-
Patent number: 11850280Abstract: The inventive subject matter includes a viral-vectored composition made of a bacterial expression vehicle expressing one or more recombinant viral protein antigens and its method of use. In particular, this invention relates to a vaccine for oral administration. Preferably, the bacterial expression vehicle is Bacillus subtilis.Type: GrantFiled: March 31, 2021Date of Patent: December 26, 2023Assignee: US Biologic, IncInventors: Jolieke Gerdy van Oosterwijk, Andrew Raymond Peters, Douglas Steven Zatechka, Jr., Luciana Meirelles Richer, Christopher Anthony Przybyszewski
-
Patent number: 11845952Abstract: One disadvantage of adeno-associated virus (AAV) is low gene expression efficiency due to delayed expression of the inserted gene. Provided is a vector plasmid for producing a vector genome to be inserted into an adeno-associated virus (AAV). The vector plasmid is provided with a vector genome cassette as a template of the vector genome, and the vector genome cassette is provided with: (1) an expression cassette including a nucleic acid molecule encoding a target gene and (b) a nucleic acid molecule encoding an expression regulatory region that allows expression of the target gene; and (2) two nucleic acid molecules positioned on both sides of the expression cassette and encoding inverted terminal repeats (ITRs). Also provided is a pharmaceutical composition containing the AVV vector, for treating or preventing an eye disease or disease associated with same.Type: GrantFiled: January 16, 2019Date of Patent: December 19, 2023Assignees: NIPPON MEDICAL SCHOOL FOUNDATION, TEIKA PHARMACEUTICAL CO., LTD.Inventors: Takashi Okada, Tsutomu Igarashi, Asaka Shiozawa
-
Patent number: 11840695Abstract: The invention relates to C. acnes strains carrying DNA vectors for the production of recombinant C. acnes phages. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a template for recombination with C. acnes phage genome leading to the insertion of a gene of interest, for the production of recombinant phages that can lead to the transgene expression into C. acnes infected by the recombinant phage. The invention encompasses, C. acnes strains containing these vectors, C. acnes recombinant phages and methods of using these recombinant phages.Type: GrantFiled: August 24, 2022Date of Patent: December 12, 2023Assignee: Eligo BioscienceInventors: Aymeric Leveau, Inès Canadas Blasco, Aurélie Mathieu, Antoine Decrulle
-
Patent number: 11834722Abstract: A method of determining the safety and/or efficacy of a gene therapy vector prior to carrying out gene therapy on an individual includes infecting a culture of induced pluripotent stem cells obtained from the individual with a gene therapy vector. Ideally the cells are allowed to differentiate, and the infection is carried out at the start of culture and at least once during differentiation and/or after differentiation. Nucleic acids are extracted from the infected cells, and then analysed to measure and/or determine adverse effects of integration of nucleic acid from the vector and/or efficiency of expression of nucleic acid from the vector.Type: GrantFiled: July 9, 2018Date of Patent: December 5, 2023Assignee: BRUNEL UNIVERSITY LONDONInventor: Michael Themis
-
Patent number: 11826414Abstract: The present disclosure provides methods related to determining the level of afucosylated Fc glycans in IgG antibodies in a biological sample from a subject. This level can be used in methods aimed at monitoring and/or treating subject suffering from an acute flavivirus infection and/or who are at risk for progression to clinically significant infection or disease. This level can also be used in a vaccination method to ensure that those who receive a flavivirus vaccine have a reduced risk of reacting to the vaccine be developing clinically significant infection or disease. The disclosure also provides treatment methods based on inhibiting Fc?RIIA or Fc?RIIIA receptor signaling. Also provided are novel cell lines that are useful in measuring afucosylated Fc glycans.Type: GrantFiled: October 22, 2018Date of Patent: November 28, 2023Assignees: CZ Biohub SF, LLC, The Board of Trustees of the Leland Stanford Junior UniversityInventor: Taia T. Wang
-
Patent number: 11820999Abstract: A lentiviral vector system for expressing a lentiviral particle is disclosed. The lentiviral vector system includes a therapeutic vector. The therapeutic vector comprises a phenylalanine hydroxylase (PAH) sequence for expressing at least one of PAH or a variant thereof, wherein the PAH sequence is truncated.Type: GrantFiled: April 2, 2018Date of Patent: November 21, 2023Assignee: American Gene Technologies International Inc.Inventors: Tyler Lahusen, Charles David Pauza